Skip to main content
SpringerLink
Log in

Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten

  • Chapter
  • First Online:
Kompendium der Psychiatrischen Pharmakotherapie

  • 8084 Accesses

Zusammenfassung

Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Medikamente zur Behandlung von Abhängigkeit und Entzugssyndromen beschrieben. Der Aufbau dieses Kapitels unterscheidet sich insofern von den anderen Kapiteln als die einzelnen Suchtmittel die Struktur vorgeben.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Andresen-Streichert H, Müller A, Glahn A et al (2018) Alkoholmarker bei klinischen und forensischen Fragestellungen. Dtsch Arztebl 115(18):309–315

    Google Scholar 

  • Anton RF, Latham P, Voronin K et al (2020) Efficacy of Gabapentin for the treatment of alcohol use disorder in patients with alcohol withdrawal symptoms: a randomized clinical trial. JAMA Intern Med 180(5):1–9

    Article  Google Scholar 

  • Barrio P, Ortega L, Guardia J et al (2018) Who receives nalmefene and how does it work in the real world? A single-arm, phase IV study of nalmefene in alcohol dependent outpatients: baseline and 1-month results. Clin Drug Investig 38(2):147–155

    Article  CAS  Google Scholar 

  • Bell J, Strang J (2020) Medication treatment of opioid use disorder. Biol Psychiatry 87(1):82–88

    Article  CAS  Google Scholar 

  • Black N, Stockings E, Campbell G et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6(12):995–1010

    Article  Google Scholar 

  • BMG (Bundesministerium für Gesundheit) (2017) https://www.bundesgesundheitsministerium.de/service/publikationen/drogen-und-sucht/details.html?bmg[pubid]=3104. Zugegriffen: 23. Apr. 2018

  • Bschor T, Henssler J, Müller M, Baethge C (2018) Baclofen for alcohol use disorder-a systematic meta-analysis. Acta Psychiatr Scand 138(3):232–242

    Article  CAS  Google Scholar 

  • Carney G, Bassett K, Maclure M et al (2020) Cardiovascular and neuropsychiatric safety of smoking cessation pharmacotherapies in non-depressed adults: a retrospective cohort study. Addiction 115(8): 1534–1546

    Article  Google Scholar 

  • Csajka C, Crettol S, Guidi M, Eap CB (2016) Population genetic-based pharmacokinetic modeling of methadone and its relationship with the QTc interval in opioid-dependent patients. Clin Pharmacokinet 55(12):1521–1533

    Article  CAS  Google Scholar 

  • Davies NM, Taylor GMJ, Taylor AE et al (2018) The effects of prescribing varenicline on two-year health outcomes: an observational cohort study using electronic medical records. Addiction 113(6):1105–1116

    Article  Google Scholar 

  • Desai RJ, Good MM, San-Juan-Rodriguez A et al (2019) Varenicline and nicotine replacement use associated with US Food and Drug Administration Drug Safety Communications. JAMA Netw Open 2(9):e1910626

    Article  Google Scholar 

  • Doran N, Dubrava S, Anthenelli RM (2019) Effects of varenicline, depressive symptoms, and region of enrollment on smoking cessation in depressed smokers. Nicotine Tob Res 21(2):156–162

    Article  CAS  Google Scholar 

  • D’Souza DC, Cortes-Briones J, Creatura G et al (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6(1):35–45

    Article  Google Scholar 

  • EMA (2018) https://www.ema.europa.eu/en/documents/overview/buvidal-epar-medicine-overview_de.pdf

  • Evins AE, Benowitz NL, West R et al (2019) Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with psychotic, anxiety, and mood disorders in the EAGLES Trial. J Clin Psychopharmacol 39(2):108–116

    Article  Google Scholar 

  • Falk DE, O’Malley SS, Witkiewitz K et al; Alcohol Clinical Trials Initiative (ACTIVE) Workgroup (2019) Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials. Jama Psychiatry 76(4):374–381

    Article  Google Scholar 

  • Gobbi G, Atkin T, Zytynski T et al (2019) Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. Jama Psychiatry 76(4):426–434

    Article  Google Scholar 

  • Gouzoulis-Mayfrank E, Härtel-Petri R, Hamdorf W et al (2017) Methamphetamine-related disorders. Dtsch Arztebl Int 114(26):455–461

    PubMed  PubMed Central  Google Scholar 

  • Heinzerling KG, Swanson AN, Hall TM et al (2014) Randomized, placebo-controlled trial of bupropion in methamphetamine-dependent participants with less than daily methamphetamine use. Addiction 109(11):1878–1886

    Article  Google Scholar 

  • Hoch E, Friemel CM, Schneider M (Hrsg) (2018) Cannabis: Potential und Risiko. Ergebnisse einer wissenschaftlichen Analyse. Springer, Berlin Heidelberg New York

    Google Scholar 

  • Hohmann N, Mikus G, Czock D (2014) Wirkungen und Risiken neuartiger psychoaktiver Substanzen. Dt Ärztebl 9:139–147

    Google Scholar 

  • Kampman KM, Pettinati HM, Lynch KG et al (2013) A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend 133(1):94–99

    Article  CAS  Google Scholar 

  • Kishi T, Sevy S, Chekuri R, Correll CU (2013) Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. Clin Psychiatry 74(7):e642–e654

    Article  Google Scholar 

  • Levin FR, Mariani J, Brooks DJ et al (2013) A randomized double-blind, placebo controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders. Addiction 108(6):1084–1094

    Article  Google Scholar 

  • Meier MH, Caspi A, Ambler A et al (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109(40):E2657–E2664

    Article  CAS  Google Scholar 

  • Rankin GD, Wingfors H, Uski O et al (2019) The toxic potential of a fourth-generation E-cigarette on human lung cell lines and tissue explants. J Appl Toxicol 39(8):1143–1154

    Article  CAS  Google Scholar 

  • Rose JE, Behm FM (2014) Combination treatment with varenicline and bupropion in an adaptive smoking cessation paradigm. Am J Psychiatry 171(11):1199–1205

    Article  Google Scholar 

  • Rüther T, Wissen F, Linhardt A et al (2016) Electronic cigarettes – attitudes and use in Germany. Nicotine Tob Res 18(5):660–669

    Article  Google Scholar 

  • Sigmon SC, Dunn KE, Saulsgiver K et al (2013) A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers. JAMA Psychiatry 70(12):1347–1354

    Article  CAS  Google Scholar 

  • Simpson TL, Saxon AJ, Stappenbeck C et al (2018) Double-blind randomized clinical trial of prazosin for alcohol use disorder. Am J Psychiatry 175(12):1216–1224

    Article  Google Scholar 

  • Soyka M (2016) Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential. Expert Opin Pharmacother 17(4):619–626

    Article  CAS  Google Scholar 

  • Soyka M, Pogarell O (2019) Neue Slow-release-Buprenorphinformulierungen zur Optimierung der Opioidsubstitution. Nervenarzt 90(9):932–937

    Article  Google Scholar 

  • Squeglia LM, Tomko RL, Baker NL et al (2018) The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend 185:17–22

    Article  CAS  Google Scholar 

  • Stapleton J, West R, Hajek P et al (2013) Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. Addiction 108(12):2193–2201

    Article  Google Scholar 

  • Sullivan JT, Sykora K, Schneiderman J et al (1989) Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 84(11):1353–1357

    Article  CAS  Google Scholar 

  • Verthein U, Beck T, Haasen C, Reimer J (2015) Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 21(2):97–104

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheim, Deutschland

    Prof. Dr. med. Falk Kiefer

  2. Mainz, Deutschland

    Otto Benkert

Authors
  1. Prof. Dr. med. Falk Kiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Otto Benkert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Otto Benkert .

Editor information

Editors and Affiliations

  1. ehemals Universitäts-Klinikum Mainz, Mainz, Germany

    Otto Benkert

  2. Klinik für Psychiatrie und Psychotherapie, ehemals Universitäts-Klinikum München Campus Innenstadt, München, Germany

    Hanns Hippius

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kiefer, F., Benkert, O. (2021). Medikamente zur Behandlung von Abhängigkeitserkrankungen und abhängigem Verhalten. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-61753-3_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-61753-3_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-61752-6

  • Online ISBN: 978-3-662-61753-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation